⏱ 2 min read
Background
Alcon, an eye-care implants and consumables group based in Geneva and Texas, has published its quarterly results. The company operates in two main areas: eye surgery (Surgical) and vision care (Vision Care). In recent months, its intraocular implants have faced competitive pressure. The group has also abandoned the implant programmes acquired from PowerVision.
The key points
In the third quarter of 2026, Alcon's revenue rose by 4.9% to 2.72 billion dollars, or 2.24 billion francs, according to the AWP news agency. Operating profit (EBIT) rose by 14.8% to 381 million dollars. Net profit reached 260 million dollars.
The Surgical division posted quarterly sales of 1.48 billion dollars (+4%), despite a 2% decline in implants, to 422 million. The Vision Care division reached 1.24 billion (+6%), driven by contact lenses (+4%) and ocular health (+8%).
Over nine months, sales grew by 7% to 8.18 billion dollars. Alcon has narrowed its annual targets: it now expects sales growth of around 6%, compared with 5 to 7% previously.
Key figures
- 2.72 billion dollars : third-quarter 2026 revenue
- 381 million dollars : quarterly EBIT, up 14.8%
- 21,8 % : core operating margin
- 402 million dollars : impairment linked to abandoning the PowerVision programmes
- 59.48 francs : share closing price on Wednesday 11 November 2026
Who says what
- David Endicott (CEO of Alcon): the company remains on track to meet its targets, despite competitive pressure in certain areas.
Analysis
- According to UBS : growth is slightly less vigorous than expected, but profitability is improving.
- According to Octavian : apart from implants, the results remain respectable.
Further reading
Sources
Let’s share Romandy’s news
We build the news together.
An idea, an opinion, a wish, a detail to add? Tell us!
